What Вальсакор Treats: Main Uses and Benefits

The medication is commonly used to help manage chronic cardiovascular conditions that place significant, ongoing strain on the circulatory system and vital organs, including managing symptoms related to circulatory strain and associated systemic factors.

It is considered relevant in contexts marked by increased discomfort or tension, including managing high blood pressure (hypertension), supporting functional stability in impaired cardiac conditions (such as chronic heart failure or post-heart attack recovery), and assisting with kidney-related functional stress in high-risk patients. This therapy assists with maintaining functional stability, which is relevant for easing the overall symptom load.

Quick Fact

Quick Fact:	Support for Physiological Stress
Primary Use Categories	Chronic Hypertension, Heart Failure, Post-MI
Relevant Symptom Focus	Elevated Arterial Pressure
Supportive Benefit	Supports stability and cardiovascular risk management

This action helps manage symptoms that create noticeable physiological strain. “Maintaining long-term stability generally contributes to supporting patients during episodes of heightened discomfort.” Its use is commonly applied when supportive symptom management is appropriate for managing signs of kidney strain, such as excessive protein in the urine, and assists with maintaining functional stability.

Regulatory References

1. NIH DailyMed Label on Valsartan

Who Can and Cannot Use Вальсакор (Valsartan)

The eligibility for Valsartan is strictly defined by government regulatory documents, focusing on life stage, specific conditions, and age boundaries.

Absolute Contraindications: Use is strictly contraindicated for women who are or may become pregnant, especially during the second and third trimesters. Patients with known hypersensitivity to Valsartan or its excipients, severe hepatic impairment, biliary cirrhosis, or cholestasis must not use the medicine. Concomitant use with aliskiren-containing products is also contraindicated in patients with Diabetes Mellitus.

Age and Condition Restrictions: Use is established for adults but is restricted for children to treating hypertension only in those 6 years of age and older. It is not recommended for children under 6 or for pediatric heart failure indications. The medicine is generally not recommended for patients with severe renal impairment (creatinine clearance le 10 mL/min) or those breastfeeding. Caution is advised for patients with renal artery stenosis, pre-existing angioedema, or mild-to-moderate hepatic impairment.

Interactions with other medicines and products

The official regulatory profile for Valsartan (Вальсакор) interactions identifies substances that pose a documented risk of additive pharmacodynamic effects or that alter systemic exposure. Co-administration with Aliskiren is a formal contraindication in specific populations, namely patients with diabetes mellitus or those with renal impairment defined by a Glomerular Filtration Rate (GFR) less than 60 mL/min/1.73 m^2. This restriction is related to the increased risks associated with dual blockade of the Renin-Angiotensin System (RAS).

Interacting Substance Category	Documented Interaction Outcome
Potassium-Sparing Agents (Diuretics, Supplements)	Increased risk of hyperkalemia (elevated serum potassium levels).
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Potential attenuation of the antihypertensive effect and increased risk of worsening renal function.
OATP1B1/OATP1B3 Inhibitors (e.g., Rifampicin)	Results in increased Valsartan plasma exposure (AUC) by affecting drug clearance.

Co-administration with Lithium may cause a reversible increase in serum Lithium concentrations, raising the risk of toxicity. While food intake can reduce Valsartan exposure, this effect is not clinically significant enough to mandate specific timing rules for administration.

AT1 Receptor Blockade: Mechanism of Action

Вальсакор (Valsacor) contains the active moiety valsartan, which functions as a competitive and selective antagonist of the angiotensin II type 1 ( AT1) receptor. Valsartan exhibits high binding affinity and selectivity for the AT1 receptor over the AT2 receptor.

This AT1 receptor blockade occurs across various target tissues, including the vascular smooth muscle and the adrenal cortex. By binding to the receptor, the molecule prevents the endogenous vasoconstrictor and aldosterone-releasing effects of angiotensin II. The molecular consequence of this action is a reduction of the inherent vasoconstrictive signaling.

This action interrupts the negative feedback loop of the renin-angiotensin-aldosterone system (RAAS), leading to a compensatory increase in plasma renin levels and angiotensin II levels. Furthermore, it results in the diminishing of pro-hypertrophic and pro-fibrotic signaling in cardiac and renal tissue, thereby decreasing the downstream effects mediated by the AT1 receptor.

How to Use Вальсакор

Вальсакор (Valsartan) is administered through the oral route, available as film-coated tablets in multiple strengths (such as 40 mg, 80 mg, 160 mg, and 320 mg) and as an oral suspension for specific patient needs. The tablets may be taken with or without food and should be swallowed whole with water.

Administration frequency is defined by the specific condition being addressed. For managing hypertension, the regimen is typically once daily, with starting doses often set at 80 mg or 160 mg, and the maximum daily dose being 320 mg. In clinical settings such as heart failure and post-myocardial infarction treatment, the administration shifts to a twice-daily schedule. The initial dose for heart failure is commonly 40 mg twice daily, while post-MI therapy may commence as low as 20 mg twice daily.

Doses for chronic conditions like heart failure are generally adjusted upward, or titrated, at intervals of at least two weeks until the maximum tolerated daily dose is achieved. If a dose is missed, the general procedure is to skip that dose and return to the regular schedule if the time for the next dose is near. Regarding population-specific instructions, for patients with mild to moderate liver impairment without cholestasis, the total daily dose should generally not exceed 80 mg. For children aged 6 to 16 years with hypertension, dosing is calculated based on body weight, starting at a lower milligram-per-kilogram ratio once daily.

Research evidence / Overview of studies for Вальсакор (Valsartan)

---

Evidence for use in Chronic Hypertension

Valsartan was studied for managing conditions characterized by sustained physiological strain related to high blood pressure. Large-scale Randomized Controlled Trials (RCTs) and long-term comparative studies were the main types of research conducted. These studies research explored the relationship between Valsartan and changes in Blood Pressure (BP) measurements and outcomes describing episodic or acute changes like the occurrence of major cardiovascular events (e.g., stroke and cardiovascular death).

Findings describe patterns observed in the studies related to changes in elevated BP levels. These research results contribute to the broader evidence landscape used by regulators to contextualize the evidence for this condition. Long-term effects are not fully established beyond the observed trial durations.

Evidence for use after a Heart Attack (Post-Myocardial Infarction) Recovery

The use of Valsartan in patients recovering from a recent heart attack was evaluated in major, multi-center trials. These trials were designed to monitor long-term outcomes like all-cause mortality and heart failure hospitalization in patients who had recently experienced an acute event and presented with conditions characterized by functional limitations following the episode.

The primary study reported measurements of all-cause mortality rates for the Valsartan group and the established ACE inhibitor comparator group over approximately two years of follow-up. The research describes that outcomes in the group receiving the dual combination therapy (Valsartan plus the ACE inhibitor) were similar to those in the monotherapy groups. Follow-up durations were limited to about two years for the core part of the primary study, meaning that information for long-term outcomes beyond that period remains uncharacterized.

Evidence for use in Chronic Heart Failure

Valsartan was studied for conditions involving periods of heightened symptoms and functional limitations related to chronic heart failure. This research utilized large-scale, multinational RCTs and systematic reviews. The trials research examined outcomes related to systemic or functional imbalance such as all-cause mortality, cardiovascular mortality, and the frequency of hospitalization for heart failure exacerbation, along with measurements of heart function.

The evidence is limited for long-term patterns in patients whose heart function is preserved (HFpEF) compared to those with reduced function (HFrEF). Additionally, patterns observed in some studies when Valsartan was associated with combination therapy with certain other established heart failure therapies were noted to be complex and remain an area of ongoing scientific evaluation.

Key Studies & References

1. Val-HeFT: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
2. VALUE trial: Valsartan Antihypertensive Long-Term Use Evaluation (ACC Trial Summary)
3. Label: VALSARTAN tablet, film coated - DailyMed - NIH (US Regulatory Document)
4. SUMMARY OF PRODUCT CHARACTERISTICS (SmPC) Diovan (Valsartan) (EU Regulatory Document)

Common questions about Вальсакор (FAQ)

Q: Can Вальсакор be used to treat high blood pressure?

According to official product information, Вальсакор (Valsartan) is primarily indicated for the treatment of essential hypertension. Essential hypertension is the medical term for high blood pressure that has no identifiable underlying cause. This usage aligns with its function as an Angiotensin II receptor blocker (ARB), a class of medicines designed to help relax and widen blood vessels.

Q: Does Вальсакор affect the heart?

Regulatory documents indicate that Вальсакор has specific applications for certain heart conditions, in addition to lowering blood pressure. It is approved for use after a recent myocardial infarction (heart attack) and for the treatment of symptomatic heart failure. These applications are included because the medicine is designed to reduce the workload on the heart, which is beneficial in these specific conditions.

Q: How does Вальсакор work to lower blood pressure?

Вальсакор contains the active substance Valsartan, which is classified as an Angiotensin II receptor blocker. This means it works by blocking the effects of the natural body substance called Angiotensin II. By inhibiting this action, the medicine encourages blood vessels to relax and widen, thereby contributing to a decrease in blood pressure.

Q: What happens if a dose of Вальсакор is missed?

According to the official product information, if a dose is forgotten, official instructions state to take the next dose at the usual scheduled time. Regulatory advice indicates that a double dose should not be taken to compensate for a missed dose. Following the prescribed regimen supports consistent blood pressure control.

Q: Can Вальсакор be taken with food?

Regulatory information specifies that Вальсакор tablets can be taken either with or without food. The medicine's absorption and efficacy are not significantly altered by its relationship to meals. This characteristic allows the medicine to be taken at a convenient time of day.

Q: How long does it take for Вальсакор to work?

The initial blood pressure reduction from a single dose typically begins within approximately 2 hours, reaching its peak effect within 4–6 hours. However, achieving the maximum and sustained effect for chronic high blood pressure often takes between two and four weeks of continuous daily treatment.

Q: Is Вальсакор used for children?

Official regulatory documents indicate that Вальсакор is approved for the treatment of high blood pressure in children and adolescents who are between 6 and 18 years of age. Usage outside of this specific age range or for other conditions is determined following consultation with a healthcare professional.

Q: What is the shelf life of Вальсакор?

Official product information specifies that Вальсакор has a shelf life of three years from the date of manufacture when stored correctly in its original packaging. Patients are advised to always check the expiration date on the packaging and follow instructions regarding disposal of expired medication.

Storage Requirements

Official regulatory documents require that Вальсакор (Valsartan) tablets and the oral suspension be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), protected from excess heat and moisture. The medication must be kept in its original container and the container must be tightly closed when not in use. It is strictly mandated that the product be kept out of the sight and reach of children.

Stability and Handling

The oral suspension form has specific stability rules: it must not be frozen and has a limited shelf-life after preparation. The suspension must be discarded after 30 days if stored at room temperature or after 75 days if stored in a refrigerator. Always follow the explicit instructions for preparing and handling the suspension, including shaking well before use.

Disposal Instructions

Expired or unused Вальсакор should be disposed of promptly through a recognized drug take-back program, if one is available. Regulatory guidelines prohibit discarding the medication by flushing it down a toilet or pouring it down a sink (wastewater) to prevent environmental contamination.